BIIB

Nasdaq

BIOGEN INC.

Health Care, Biotechnology

$207.94

close 7 Aug 2026

+62.45%

52-week change

$30.70B

market cap

$127.71

$219.72

52-week range

Valuation

Market cap$30.70B

P/E (TTM / 5y avg)22.36x18.51x

Forward P/E (FY2026 / FY2027)16.70x12.53x

PEG (TTM / fwd)—0.50

P/S (TTM)3.09x

P/B1.65x

EV/EBITDA (TTM)12.77x

FCF yield (TTM)7.89%

Cash flow & dividend

FCF (TTM)$2.42B

FCF per share (TTM)$16.41

FCF margin (TTM)24.38%

Dividend yield (indicated / 5y avg)——

Annualized dividend—

Payout ratio (EPS / FCF)——

Growth & quality

Revenue YoY, latest Q+1.93%

Diluted EPS YoY, latest Q+31.10%

Operating margin (TTM)—

Net margin (TTM)13.81%

ROE (latest FY)7.08%

Net debt / EBITDA (TTM)1.40

Interest coverage (TTM)—

Price

-39.24%-9.52%/yrover 5y

Weekly closes · split-adjusted

close 7 Aug 2026

Fundamentals

Fiscal years, last 10, CAGR chips on growth series, plus a dimmed trailing-twelve-month bar

Revenue

5Y CAGR -5.96%10Y CAGR -0.84%

Diluted EPS

5Y CAGR -18.73%10Y CAGR -5.42%

FCF per share

5Y CAGR -9.98%10Y CAGR -0.16%

Operating cash flow

5Y CAGR -12.22%10Y CAGR -5.59%

Free cash flow

5Y CAGR -11.63%10Y CAGR -4.58%

Operating margin

FCF margin

Return on equity

Return on capital employed

Shares outstanding

5Y CAGR -0.75%10Y CAGR -3.90%

Net debt / EBITDA

Interest coverage

Earnings

Street estimates, not SEC filings

Next / Q3 FY26

Date28 Oct 2026

EPS estimate$2.37

Revenue estimate$2.66B

Last reported

Date—

EPS——

Revenue——